One such series composes of LA with attached N-benzylpiperidine hybrids (Figure 12) to target three AD therapeutic objectives: (i) AChE; (ii) β-secretase-1 (BACE1) and (iii) σ-1 receptor (σ1R).147. This evidence concerns the gene ACHE and Alzheimer disease.